Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Centessa Pharmaceuticals stock

Learn how to easily invest in Centessa Pharmaceuticals stock.

Centessa Pharmaceuticals PLC ADR is a biotechnology business based in the US. Centessa Pharmaceuticals shares (CNTA) are listed on the NASDAQ and all prices are listed in US Dollars. Centessa Pharmaceuticals employs 90 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Centessa Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CNTA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Centessa Pharmaceuticals stock price (NASDAQ: CNTA)

Use our graph to track the performance of CNTA stocks over time.

Centessa Pharmaceuticals shares at a glance

Information last updated 2022-07-02.
Latest market close$4.98
52-week range$2.89 - $25.98
50-day moving average $5.61
200-day moving average $10.14
Wall St. target price$10.75
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.30

Buy Centessa Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you open a Robinhood account
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Centessa Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Centessa Pharmaceuticals price performance over time

Historical closes compared with the close of $4.98 from 2022-07-05

1 week (2022-06-28) 8.03%
1 month (2022-06-06) 56.60%
3 months (2022-04-06) -48.82%
6 months (2022-01-06) -44.61%
1 year (2021-07-06) -77.17%
2 years (2020-07-02) N/A
3 years (2019-07-02) N/A
5 years (2017-07-02) N/A

Centessa Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -24.1%
Return on equity TTM -51.89%
Profit margin 0%
Book value $5.11
Market capitalisation $486.2 million

TTM: trailing 12 months

Centessa Pharmaceuticals share dividends

We're not expecting Centessa Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

Centessa Pharmaceuticals overview

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom. .

Frequently asked questions

What percentage of Centessa Pharmaceuticals is owned by insiders or institutions?
Currently 1.232% of Centessa Pharmaceuticals shares are held by insiders and 85.229% by institutions.
How many people work for Centessa Pharmaceuticals?
Latest data suggests 90 work at Centessa Pharmaceuticals.
When does the fiscal year end for Centessa Pharmaceuticals?
Centessa Pharmaceuticals's fiscal year ends in December.
Where is Centessa Pharmaceuticals based?
Centessa Pharmaceuticals's address is: 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT
What is Centessa Pharmaceuticals's ISIN number?
Centessa Pharmaceuticals's international securities identification number is: US1523091007

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site